MINERVA NEUROSC. DL-0001
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone for the treatment of negative symptoms in patients with schizophrenia. The company also has exclusive rights to develop and commercialize MIN-301, a soluble r… Read more
Market Cap & Net Worth: MINERVA NEUROSC. DL-0001 (4MNA)
MINERVA NEUROSC. DL-0001 (F:4MNA) has a market capitalization of $48.46 Million (€47.21 Million) as of March 19, 2026. Listed on the F stock exchange, this Germany-based company holds position #23922 globally and #2609 in its home market, demonstrating a 35.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying MINERVA NEUROSC. DL-0001's stock price €6.75 by its total outstanding shares 6993406 (6.99 Million).
MINERVA NEUROSC. DL-0001 Market Cap History: 2016 to 2026
MINERVA NEUROSC. DL-0001's market capitalization history from 2016 to 2026. Data shows change from $636.19 Million to $48.46 Million (-23.14% CAGR).
MINERVA NEUROSC. DL-0001 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how MINERVA NEUROSC. DL-0001's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 4MNA by Market Capitalization
Companies near MINERVA NEUROSC. DL-0001 in the global market cap rankings as of March 19, 2026.
Key companies related to MINERVA NEUROSC. DL-0001 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #165 globally with a market cap of $114.33 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #285 globally with a market cap of $73.32 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #340 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #497 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #165 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $114.33 Billion | $451.59 |
| #285 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $73.32 Billion | $744.12 |
| #340 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #497 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
MINERVA NEUROSC. DL-0001 Historical Marketcap From 2016 to 2026
Between 2016 and today, MINERVA NEUROSC. DL-0001's market cap moved from $636.19 Million to $ 48.46 Million, with a yearly change of -23.14%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €48.46 Million | +99.70% |
| 2025 | €24.26 Million | +64.08% |
| 2024 | €14.79 Million | -64.05% |
| 2023 | €41.13 Million | +312.82% |
| 2022 | €9.96 Million | -75.20% |
| 2021 | €40.17 Million | -60.92% |
| 2020 | €102.80 Million | -70.17% |
| 2019 | €344.57 Million | +8.50% |
| 2018 | €317.58 Million | +6.10% |
| 2017 | €299.32 Million | -52.95% |
| 2016 | €636.19 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 19th, 2026 the market cap of MINERVA NEUROSC. DL-0001 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $48.46 Million USD |
| MoneyControl | $48.46 Million USD |
| MarketWatch | $48.46 Million USD |
| marketcap.company | $48.46 Million USD |
| Reuters | $48.46 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.